Kodiak Sciences (KOD)
(Delayed Data from NSDQ)
$6.43 USD
+0.24 (3.88%)
Updated Nov 25, 2024 04:00 PM ET
3-Hold of 5 3
D Value A Growth C Momentum C VGM
Price, Consensus and EPS Surprise
KOD 6.43 +0.24(3.88%)
Will KOD be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for KOD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for KOD
Kodiak Sciences Inc. (KOD) Just Flashed Golden Cross Signal: Do You Buy?
Kodiak Q3 Loss Narrower Than Expected, Pipeline Development in Focus
KOD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Kodiak Counts on Tarcocimab Eye Disease Program Despite Setbacks
Why Is Kodiak Sciences (KOD) Down 8.1% Since Last Earnings Report?
Kodiak (KOD) Q2 Loss Narrower Than Expected, Pipeline in Focus
Other News for KOD
Kodiak: Tarcocimab Faces High Barriers To Entry Despite Resurrection (Rating Upgrade)
Cautious Approach: Kodiak Sciences’ Retinal Pipeline Progress and Hold Rating
Kodiak Sciences price target raised to $4 from $3 at Barclays
Kodiak Sciences price target raised by $1 at Barclays, here's why
Barclays Remains a Sell on Kodiak Sciences (KOD)